D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $1 from $12 and keeps a Buy rating on the shares after the ...

Researchers at the University of Cologne and University Hospital Cologne have determined that the novel mRNA-based COVID-19 ...

After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...

Another round of layoffs leaves a University of Pennsylvania spinout with only seven employees just a year after its staff ...

Researchers have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against potential ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a revised operating plan focused on evaluating strategic alternatives ...

According to a new research the combination of serum Monocyte Chemoattractant Protein-1 (MCP-1) and Osteopontin (OPN) has a ...

Researchers identified a monocyte/dendritic cell response to EBV reactivation in B cells as one of the earliest events in ...

Researchers at the University of Cologne have found that mRNA-based COVID-19 vaccines have a lasting impact on the innate ...